Audit: QRS - Lactobacillus salivarius for Health & Longevity
Audit conducted on 29/06/2026 01:19 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 91 |
| Failed | 0 |
| N/A | 0 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol values, benefits, risks, markers, and qualitative items trace to the ER. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “theoretical antibiotic-resistance gene transfer” mirrors ER §Speculative risks; modest/limited framing preserved. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening/softening observed. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications/Interactions come from the ER Key Interactions & Contraindications section; benefits/risks from their respective sections. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Only strain names (WB21) and drug examples appear, all present in the ER for the same facts; no PMIDs/NCTs introduced. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No new attributions. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Tone matches the ER’s measured, strain-specific framing. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Maintained throughout. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence, not directives. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No advice phrasing; footer disclaimer present. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Information-presenting voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language with glosses where needed. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact card layout. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing reflects this audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol detail (split dosing, 8–12 week courses) reflects this. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not general-population framed. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Risk/benefit weighting preserved from ER. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. | 🟢 | No “anti-aging” usage. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. | 🟢 | Uses “lozenge”, “capsule”, “adverse” register; no colloquialisms. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified (card/section headings, gate headings, tier labels, Monitoring column headers). | 🟢 | “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”, “Contraindications”, “Key Interactions”, tier labels, and “Marker/Target/Why” all intact. |
| 3.2 | All “…” from the [qrs_template] are present in the QRS. | 🟢 | All non-repeating spans present; repeating marker_#/qualitative_item_# expanded to numbered instances. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Untouched spans (page_title, etc.) unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. | 🟢 | High benefit/risk tiers correctly hidden via display:none rather than text-filled. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Tier labels and marker names match ER. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels faithful to ER. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). | 🟢 | No emoji indicators; color via CSS/bold. |
| 4.5 | The QRS is designed to render on one A4 page; over-budget sections are condensed, not extended. | 🟢 | Content condensed to fit one page. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Comment block at lines 2–14, first element. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. | 🟢 | YAML delimited by — at lines 3 and 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Inside HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required by YAML. | 🟢 | duration quoted (contains colon); others clean. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]”. | 🟢 | er_filename: lactobacillus_salivarius_2026-0629-0053_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”. | 🟢 | qrs_prompt_version: 26.5.18 |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]”. | 🟢 | qrs_creation_date: 2026-0629-0053 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: […]”. | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. | 🟢 | “Opus”. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: […]”. | 🟢 | qrs_creator_ai_fullname: Opus 4.8 |
| 5.11 | The full name of the AI consists of the nickname and the model version number and no additional qualifier. | 🟢 | “Opus 4.8”. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]”. | 🟢 | qrs_filename: lactobacillus_salivarius_2026-0629-0053_Opus_QRS.html |
| 5.13 | All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required by YAML. | 🟢 | Values clean and consistent. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The canonical_topic is HTML-entity-encoded as needed. | 🟢 | “Lactobacillus salivarius for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. | 🟢 | “Lactobacillus salivarius for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]. | 🟢 | “06/29/2026” from 2026-0629. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname]. | 🟢 | “Opus 4.8”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header limited to standard subline. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section. |
🟢 | Distills ER Conclusion (lines 430–432). |
| 7.2 | [at_a_glance] is no longer than 60 words. | 🟢 | 50 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Oral-health, breastfeeding, strain-specificity, safety all in Conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead. | 🟢 | “food-grade probiotic”, “oral health”, “immune-weakened” — all plain. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values). | 🟢 | No trial citations. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results. | 🟢 | No effect sizes or statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section. |
🟢 | Derived from ER “Populations who should avoid” bullet (line 293). |
| 8.2 | [stop_items] represent the Contraindications from the ER. | 🟢 | Immunocompromised, critically ill, catheters/valves, gut-barrier disorders. |
| 8.3 | Individual [stop_items] are formatted as <li></li>. | 🟢 | Four <li> elements. |
| 8.4 | Items are as concise as possible. No trailing explanations/elaborations/rationale/attributions/citations/study details. No content after an em/en/hyphen dash. | 🟢 | No trailing clauses; concise facts only. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as concise as possible. | 🟢 | “(e.g. short-bowel syndrome)” preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) normalize to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation present in source bullet. |
| 8.7 | If no [stop_items] are present the section is left empty. | 🟢 | Stop items are present; section populated. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section. |
🟢 | Derived from ER interaction bullets (lines 283–291). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications. | 🟢 | Five interactions; the “avoid” population bullet correctly excluded (used as contraindications). |
| 9.3 | Individual [caution_items] are formatted as <li></li>. | 🟢 | Five <li> elements. |
| 9.4 | Items are as concise as possible. No trailing explanations/rationale/attributions/citations/study details. No content after an em/en/hyphen dash. | 🟢 | “Severity:/Mitigation:” trailing detail stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as concise as possible. | 🟢 | Drug examples (amoxicillin, metronidazole, clindamycin; tacrolimus) and inulin preserved. |
| 9.6 | When the ER uses ranking notation inside parens normalize to a plain comma-separated list. | 🟢 | No ranking notation present. |
| 9.7 | If no [caution_items] are present the section is left empty. | 🟢 | Caution items are present; section populated. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section. |
🟢 | Values from ER Therapeutic Protocol (lines 313–319). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section. |
🟢 | Oral-health protocol, systemic/gut protocol, best time of day. |
| 10.3 | If less than three distinct actionable aspects are mentioned, unused sets are left empty and made invisible. | 🟢 | All three sets are used with ER content. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | CFU ranges, formats, and timing all match ER. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER. | 🟢 | Bad breath/plaque, periodontal/caries, microbiota/immune — from ER Practical Considerations (line 364). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit. | 🟢 | Oral (Medium tier) first, then periodontal/caries, then microbiota/immune (speculative). |
| 11.3 | If less than three distinct time-to-effect aspects are mentioned, unused sets are left empty and made invisible. | 🟢 | All three used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “1–2 weeks”, “8–12 weeks to 12 months”, “Within days” match ER. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel. |
🟢 | ER provides time-to-effect; section retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section. |
🟢 | Derived from ER Expected Benefits (lines 147–207). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]. | 🟢 | All four present; high hidden. |
| 12.3 | Items are as concise as possible. No explanations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. | 🟢 | Condensed subheadings only. |
| 12.4 | Parenthetical content — effect sizes, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. | 🟢 | Magnitudes and study notes stripped; only “(bad breath)” plain-language gloss retained. |
| 12.5 | If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. | 🟢 | benefits_high set to display:none (no High benefit in ER). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section. |
🟢 | Derived from ER Potential Risks (lines 225–263). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]. | 🟢 | All four present; high hidden. |
| 13.3 | Items are as concise as possible. No explanations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. | 🟢 | Condensed to facts. |
| 13.4 | Parenthetical content — frequencies, severity grades, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. | 🟢 | Magnitude lines stripped. |
| 13.5 | If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. | 🟢 | risks_high set to display:none (no High risk in ER). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section. |
🟢 | From ER Monitoring Protocol table (lines 394–400). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed. |
🟢 | All five ER biomarkers listed (periodontal indices, S. mutans, halitosis, SCORAD, immune/barrier). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. Not left placeholder or empty. |
🟢 | Cadence from ER line 392 (“reassess at roughly 4 and 8–12 weeks…”). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section. |
🟢 | From ER qualitative markers (lines 404–408). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed. |
🟢 | All five qualitative markers listed verbatim. |
Issues 29/06/2026 01:19
Pass rate 100.00%. No issues found.